Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
AssigneeBavarian Nordic A/S
InventorsRobin Steigerwald, Markus Kalla
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
Claims28
1-24. (canceled)
A recombinant modified vaccinia virus Ankara (MVA) comprising a poxviral promoter operably linked to a first nucleotide sequence, the first nucleotide sequence encoding for a structural polyprotein of an equine encephalitis virus (EEV), wherein a nucleotide sequence encoding for a capsid protein is excluded.
The recombinant MVA of claim 27, wherein the first nucleotide sequence encoding for the structural polyprotein is derived from an eastern equine encephalitis virus.
A method for treating and/or preventing in a subject an equine encephalitis virus (EEV) caused disease comprising administering to the subject a recombinant modified vaccinia virus Ankara (MVA) comprising a poxviral promoter operably linked to a first nucleotide sequence, the first nucleotide sequence encoding for a structural polyprotein of an EEV, wherein a nucleotide sequence encoding for a capsid protein is excluded.
Dependencies are inferred from the claim text.